Lifeboat Foundation

Of India’s 10 SaaS unicorns, six reached that milestone in 2,020 and investors around the world are paying attention. Last year, investors pumped $1.5 billion into Indian SaaS companies, four times more than in 2018 or 2,019 according to the SaaSBoomi report.

More than two decades ago, India began its transformation into a global IT powerhouse, ushering in an era of wealth and job creation never before seen in the country.

Now, Asia’s third largest economy is ready for the next big frontier in tech: Coming up with a new generation of software companies like Zoom or Slack.

Continue reading “India’s got the next big thing in tech, and it could be worth $1 trillion” »

face_with_colon_three Basically we simply waste chemicals that are sometimes used in compost but actually have literally millions of tons of chemicals gone to waste rather reclaiming these very expensive chemicals. For instance some medicine costs thousands of dollars to make and will not recycle completely even current compost problems are not seeing the literally value of wasted medical refuse dissolved in waste water. Literally possibly trillion dollars or more down the drain from waste but this new reclaiming system will reap the benefits 😗 Even new innovative recycled toilet paper is a new concept but someday even vital chemicals will not be wasted with these new reclaiming systems.

With sometimes offbeat technology, innovators seek to extract certain chemicals from municipal waste by.

Continue reading “Tapping sewage as a source of useful materials” »

CRISPR technology offers the promise to cure any human genetic disease with gene editing; which one will be the first?

CRISPR-Cas9 was first used as a gene-editing tool in 2012. In just a few years, the technology has exploded in popularity thanks to its promise of making gene editing much faster, cheaper, and easier than ever before.

CRISPR is short for ‘clustered regularly interspaced short palindromic repeats.’ The term makes reference to a series of repetitive patterns found in the DNA of bacteria that form the basis of a primitive immune system, defending them from viral invaders by cutting their DNA.

Amit Awasthi, an immunologist with the Translational Health Science and Technology Institute in India and corresponding author of the study, says he and his colleagues pursued this line of inquiry because previous research had linked high salt intake with autoimmune diseases, suggesting that increased salt stimulates immune cells. Meanwhile, tumors are well known to grow in immune-suppressive environments.

ABOVE: © ISTOCK.COM, CHAOFANN

In mice, a diet high in salt suppresses tumor growth—but only when gut microbes are there to stimulate immune cells, a September 10 study in Science Advances reports. The findings raise tantalizing questions about the role of diet and gut microbes in human cancers, and may point to new avenues for therapeutic development.

Continue reading “Salty Diet Helps Gut Bugs Fight Cancer in Mice: Study” »

Yes he starts with his personal controversy, emerging challenges, TAME, longevity is moving along well but has a long way to go.

Dr. Aubrey de Grey discusses the changing priorities at the forefront of the field of longevity rejuvenation research at Lifespan.io’s 2021 EARD conference. “The crusade is accelerating”, says Dr. De Grey, “but there’s so much still to do.”
De Grey is the author of The Mitochondrial Free Radical Theory of Aging (1999) and co-author of Ending Aging (2007). He is an international adjunct professor of the Moscow Institute of Physics and Technology, a fellow of the Gerontological Society of America, the American Aging Association, and the Institute for Ethics and Emerging Technologies.

Continue reading “Dr. Aubrey de Grey — Changing Priorities in Rejuvenation Technologies — Lifespan.io” »

Scientists in the U.S. and U.K. have recently grown seven miniature human organs and housed them together on a chip to create a human-on-a-chip, a whole body biomimetic device. These clusters of assembled cells mimic how organs in the body function, both separately and in tandem.

The chip could take the place of animal and tissue testing for drugs in pharmaceutical development, say its creators. It will have to win regulatory approval in each country looking to use it for tests, and it could allow for insights into how organs interact, says Linda Griffith, professor of biological and mechanical engineering at the Massachusetts Institute of Technology.

Griffith heads The PhysioMimetics program at MIT, which has collaborated with CN Bio Innovations, a British company that creates live organ-on-a-chip devices. The $26.3-million development program is funded by the Defense Advanced Research Projects Agency.

Ancient DNA extracted from human bones has rewritten early Japanese history by underlining that modern day populations in Japan have a tripartite genetic origin—a finding that refines previously accepted views of a dual genomic ancestry.

Twelve newly sequenced ancient Japanese genomes show that modern day populations do indeed show the genetic signatures of early indigenous Jomon hunter-gatherer-fishers and immigrant Yayoi farmers—but also add a third genetic component that is linked to the Kofun peoples, whose culture spread in Japan between the 3^rd and 7^th centuries.

Altana AI, a startup building a database for global supply chain networks, today announced that it raised $15 million in a series A funding round led by GV with participation from Floating Point, Ridgeline Partners, Amadeus Capital Partners, and Schematic Ventures. The proceeds, which bring the company’s total raised to $22 million to date, will be used to further develop Altana’s data and AI systems and launch new machine learning and network analysis tools, according to CEO Evan Smith.

Trade wars, the rise of ecommerce, pandemic supply chain shocks, and sustainability concerns are driving fundamental changes to supply chain networks and global trade flows. Nearly 75% of companies report supply chain disruptions in some capacity due to pandemic-related transportation restrictions. And in a recent IBM survey, 40% of executives stressed the need for spare capacity to weather future crises.

Altana’s product aims to solve these challenges with a platform that connects and learns from billions of supply chain data points. It answers questions about products, shipments, companies, and networks, filtering out illicit trade and targeting bad actors and security threats across global commerce networks.

He explored the possibility of using gene therapy or gene editing—technologies that were dominating headlines for their ability to tackle other rare genetic disorders. But scientists told him those approaches would be difficult to implement for Dravet. Instead, a newfangled idea called transfer RNA (tRNA) therapy seemed like it might be the answer.

Drug Discovery tRNA therapies could help restore proteins lost in translation.

A new class of therapies based on transfer RNA could treat forms of cystic fibrosis, muscular dystrophy, genetic epilepsies, and more by.

Continue reading “TRNA therapies could help restore proteins lost in translation” »